Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus FOSFOMYCIN TROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus FOSFOMYCIN TROMETHAMINE.
COR-OTICIN vs FOSFOMYCIN TROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
1-2 drops in each affected ear twice daily for 7 days.
3 g orally once as a single dose for uncomplicated urinary tract infection.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Category C
Category A/B
Topical Corticosteroid + Antibiotic
Antibiotic